Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1954 1
1955 1
1961 1
1969 2
1972 1
1976 2
1985 3
1986 1
1987 2
1989 3
1990 3
1992 1
1993 3
1994 4
1995 5
1996 3
1997 1
1998 7
1999 6
2000 5
2001 14
2002 10
2003 4
2004 11
2005 11
2006 13
2007 12
2008 11
2009 9
2010 12
2011 13
2012 23
2013 17
2014 20
2015 22
2016 25
2017 24
2018 36
2019 29
2020 29
2021 43
2022 57
2023 58
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: bateman rj. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
Alzheimer's disease.
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Masters CL, et al. Among authors: bateman r. Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Nat Rev Dis Primers. 2015. PMID: 27188934 Free article. Review.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: bateman rj. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Lucey BP, et al. Among authors: bateman rj. Ann Neurol. 2023 Jul;94(1):27-40. doi: 10.1002/ana.26641. Epub 2023 Apr 20. Ann Neurol. 2023. PMID: 36897120 Clinical Trial.
Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid.
Drieu A, Du S, Storck SE, Rustenhoven J, Papadopoulos Z, Dykstra T, Zhong F, Kim K, Blackburn S, Mamuladze T, Harari O, Karch CM, Bateman RJ, Perrin R, Farlow M, Chhatwal J; Dominantly Inherited Alzheimer Network; Hu S, Randolph GJ, Smirnov I, Kipnis J. Drieu A, et al. Among authors: bateman rj. Nature. 2022 Nov;611(7936):585-593. doi: 10.1038/s41586-022-05397-3. Epub 2022 Nov 9. Nature. 2022. PMID: 36352225 Free PMC article.
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O. Janelidze S, et al. Among authors: bateman rj. Brain. 2023 Apr 19;146(4):1592-1601. doi: 10.1093/brain/awac333. Brain. 2023. PMID: 36087307 Free PMC article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers.
Brase L, You SF, D'Oliveira Albanus R, Del-Aguila JL, Dai Y, Novotny BC, Soriano-Tarraga C, Dykstra T, Fernandez MV, Budde JP, Bergmann K, Morris JC, Bateman RJ, Perrin RJ, McDade E, Xiong C, Goate AM, Farlow M; Dominantly Inherited Alzheimer Network (DIAN); Sutherland GT, Kipnis J, Karch CM, Benitez BA, Harari O. Brase L, et al. Among authors: bateman rj. Nat Commun. 2023 Apr 21;14(1):2314. doi: 10.1038/s41467-023-37437-5. Nat Commun. 2023. PMID: 37085492 Free PMC article.
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, Ping L, Duong DM, Epstein MP, McDade E, Barthélemy NR, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Wingo AP, Wingo TS, Chhatwal JP, Day GS, Noble JM, Berman SB, Martins R, Graff-Radford NR, Schofield PR, Ikeuchi T, Mori H, Levin J, Farlow M, Lah JJ, Haass C, Jucker M, Morris JC, Benzinger TLS, Roberts BR, Bateman RJ, Fagan AM, Seyfried NT, Levey AI; Dominantly Inherited Alzheimer Network. Johnson ECB, et al. Among authors: bateman rj. Nat Med. 2023 Aug;29(8):1979-1988. doi: 10.1038/s41591-023-02476-4. Epub 2023 Aug 7. Nat Med. 2023. PMID: 37550416 Free PMC article.
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Li Y, et al. Among authors: bateman rj. Neurology. 2022 Feb 15;98(7):e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14. Neurology. 2022. PMID: 34906975 Free PMC article.
533 results